Trial Profile
Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2020
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Pravastatin
- Indications Liver cancer; Liver cirrhosis
- Focus Therapeutic Use
- Acronyms PRODIGE 11
- 12 May 2019 Primary endpoint (Overall survival (sorafenib-pravastatine versus sorafenib alone )) has not been met, according to the results published in the Journal of Hepatology.
- 12 May 2019 Safety and efficacy results published in the Journal of Hepatology.
- 09 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database record.